Wachovia Downgrades Valeant Pharmaceuticals (VRX) to Underperform; Risk/Reward Unfavorable
Tweet Send to a Friend
Wachovia downgrades Valeant Pharmaceuticals (NYSE: VRX) to Underperform. Valuation Range: $15 to $17.
Wachovia analyst says, "Three factors for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wachovia analyst says, "Three factors for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
